First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial

BACKGROUND: ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐line) treatment of patients with advanced non‐squamous non‐small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryun, Sugawara, Shunichi, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Inui, Naoki, Hida, Toyoaki, Lee, Ki Hyeong, Yoshida, Tatsuya, Tanaka, Hiroshi, Yang, Cheng‐Ta, Nishio, Makoto, Ohe, Yuichiro, Tamura, Tomohide, Yamamoto, Nobuyuki, Yu, Chong‐Jen, Akamatsu, Hiroaki, Takahashi, Shigeru, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501244/
https://www.ncbi.nlm.nih.gov/pubmed/37641544
http://dx.doi.org/10.1002/cam4.6348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501244/
https://www.ncbi.nlm.nih.gov/pubmed/37641544
http://dx.doi.org/10.1002/cam4.6348

Ejemplares similares